References
- Paliani U, Cardona A. COVID-19 and hydroxychloroquine: let the available data speak for themselves. Eur J Intern Med. 2020;80:121. doi:10.1016/j.ejim.2020.07.017
- WHO Statement regarding cluster of pneumonia cases in Wuhan, China; 2020; Available from: https://www.who.int/china/news/detail/09-01-2020-who-statement-regarding-cluster-of-pneumonia-cases-in-wuhan-china. Accessed October 22, 2020.
- OCEBM Levels of Evidence Working Group. The Oxford 2011 levels of evidence. Oxford Center of EBM; 2011. Available from: http://www.cebm.net/index.aspx?o=5653. Accessed June 25, 2020.
- Mehra MR, Desai SS, Kuy S, Henry TD, Patel AN. Retraction: cardiovascular disease, drug therapy, and mortality in Covid-19. N Engl J Med. doi:10.1056/NEJMoa2007621.
- Retracted coronavirus (COVID-19) papers. Available from: https://retractionwatch.com/retracted-coronavirus-covid-19-papers/. Accessed October 22, 2020.
- Pericàs JM, Arenas A, Torrallardona-Murphy O, Valero H, Nicolás D. Published evidence on COVID-19 in top-ranked journals: a descriptive study. Eur J Intern Med. 2020;79:120–122. doi:10.1016/j.ejim.2020.07.005
- Kissler SM, Tedijanto C, Goldstein E, Grad YH, Lipsitch M. Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period. Science 2020;368(6493):860–868. doi:10.1126/science.abb5793
- Watson J, Adler A, Amaravadi A, et al. Open letter to MR Mehra SS, Desai, F Ruschitzka, and AN Patel, authors of “Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis.”. Lancet. 2020.
- Mehra MR, Desai SS, Ruschitzka F, Patel AN. RETRACTED: hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. Lancet. 2020. doi:10.1016/S0140-6736(20)31180-6.
- Frieden TR, Drazen JM, Harrington DP, McMurray JJV, Ware JH, Woodcock J. Evidence for health decision making - beyond randomized, controlled trials. N Engl J Med. 2017;377(5):465–475. doi:10.1056/NEJMra1614394